Brief: Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone

Nicox SA

23/03/2021 06:45

March 23 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX’S NCX 470 MONT BLANC PHASE 3 GLAUCOMA TRIAL REACHES
50%
ENROLLMENT MILESTONE
    * CURRENTLY ON TRACK FOR TOP-LINE RESULTS IN Q2 2022
    * 338 PATIENTS RANDOMIZED AS OF MARCH 22, 2021, OUT OF A
TARGET OF
670

Source text for Eikon:  ID:nGNX2T6JM3 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))